Literature DB >> 21755538

Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies.

Peggy Reiner1, Damien Galanaud, Gaëlle Leroux, Marie Vidailhet, Julien Haroche, Du Le Thi Huong, Camille Francès, Thomas Papo, Christian de Gennes, Lucile Musset, Bertrand Wechsler, Zahir Amoura, Jean-Charles Piette, Nathalie Costedoat-Chalumeau.   

Abstract

OBJECTIVE: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome.
METHODS: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients.
RESULTS: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ± 11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases.
CONCLUSIONS: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755538     DOI: 10.1002/mds.23863

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

Review 1.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 2.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

Review 3.  Neurological Complications in Patients with Systemic Lupus Erythematosus.

Authors:  Amir Shaban; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 6.030

Review 4.  Neurological Disease in Lupus: Toward a Personalized Medicine Approach.

Authors:  Sarah McGlasson; Stewart Wiseman; Joanna Wardlaw; Neeraj Dhaun; David P J Hunt
Journal:  Front Immunol       Date:  2018-06-06       Impact factor: 8.786

Review 5.  Treatable Hyperkinetic Movement Disorders Not to Be Missed.

Authors:  Aurélie Méneret; Béatrice Garcin; Solène Frismand; Annie Lannuzel; Louise-Laure Mariani; Emmanuel Roze
Journal:  Front Neurol       Date:  2021-12-01       Impact factor: 4.003

Review 6.  Autoimmune and Paraneoplastic Chorea: A Review of the Literature.

Authors:  Kevin Kyle; Yvette Bordelon; Nagagopal Venna; Jenny Linnoila
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

7.  Antiphospholipid-related chorea.

Authors:  Silvio Peluso; Antonella Antenora; Anna De Rosa; Alessandro Roca; Gennaro Maddaluno; Vincenzo Brescia Morra; Giuseppe De Michele
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

8.  Chorea as the first sign in a patient with elderly-onset systemic lupus erythematosus.

Authors:  Yuko Ariizumi; Tetsutaro Ozawa; Takayoshi Tokutake; Izumi Kawachi; Masaki Hirose; Shinichi Katada; Shuichi Igarashi; Keiko Tanaka; Masatoyo Nishizawa
Journal:  Case Rep Neurol Med       Date:  2012-02-13

9.  Difficult diagnoses in hyperkinetic disorders - a focused review.

Authors:  Francisco Cardoso
Journal:  Front Neurol       Date:  2012-10-29       Impact factor: 4.003

10.  SLE presenting as migratory arthritis, chorea and nephritis.

Authors:  Sajal Ajmani; Durga Prasanna Misra; Able Lawrence
Journal:  Mediterr J Rheumatol       Date:  2018-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.